DK2897611T3 - Fremgangsmåder til behandling af hepatitis c - Google Patents

Fremgangsmåder til behandling af hepatitis c Download PDF

Info

Publication number: DK2897611T3
Authority: DK; Denmark
Prior art keywords: methods; treating hepatitis; hepatitis; treating
Prior art date: 2012-09-18

Application number

DK13773463T

Other languages

English (en)

Inventor

Teresa Ng (lok-Chan)

Tami J Pilot-Matias

Warren M Kati

Preethi Krishnan

Clarence J Maring

Neeta C Mistry

Thomas J Reisch

Rolf Wagner

John K Pratt

Mark A Matulenko

Ryan G Keddy

Dachun Liu

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-18

Filing date

2013-09-17

Publication date

2019-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2897611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-17 Application filed by Abbvie Inc filed Critical Abbvie Inc

2019-11-04 Application granted granted Critical

2019-11-04 Publication of DK2897611T3 publication Critical patent/DK2897611T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK13773463T 2012-09-18 2013-09-17 Fremgangsmåder til behandling af hepatitis c DK2897611T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261702564P	2012-09-18	2012-09-18
PCT/US2013/060103 WO2014047039A1 (en)	2012-09-18	2013-09-17	Methods for treating hepatitis c

Publications (1)

Publication Number	Publication Date
DK2897611T3 true DK2897611T3 (da)	2019-11-04

Family

ID=49304326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13773463T DK2897611T3 (da)	2012-09-18	2013-09-17	Fremgangsmåder til behandling af hepatitis c

Country Status (25)

Country	Link
US (1)	US20140080868A1 (da)
EP (2)	EP2897611B1 (da)
JP (4)	JP6297044B2 (da)
CN (1)	CN104797253A (da)
AU (2)	AU2013318302B2 (da)
BR (1)	BR112015006037B1 (da)
CA (1)	CA2884539C (da)
CY (1)	CY1122442T1 (da)
DK (1)	DK2897611T3 (da)
ES (1)	ES2755089T3 (da)
HK (1)	HK1209319A1 (da)
HR (1)	HRP20191939T1 (da)
HU (1)	HUE046544T2 (da)
LT (1)	LT2897611T (da)
MX (2)	MX367796B (da)
NZ (1)	NZ630581A (da)
PL (1)	PL2897611T3 (da)
PT (1)	PT2897611T (da)
RS (1)	RS59640B1 (da)
RU (1)	RU2665365C2 (da)
SG (2)	SG11201502095SA (da)
SI (1)	SI2897611T1 (da)
TW (1)	TWI621436B (da)
WO (1)	WO2014047039A1 (da)
ZA (1)	ZA201501752B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX367796B (es) *	2012-09-18	2019-09-06	Abbvie Inc	Usos médicos para tratar hepatitis c.
WO2015153792A1 (en) *	2014-04-02	2015-10-08	Abbvie Inc.	Methods for treating hcv
KR102210935B1 (ko) *	2013-03-14	2021-02-02	애브비 인코포레이티드	C형 간염 치료용 2가지 항바이러스제의 병용물
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
BR112016022976A8 (pt)	2014-04-02	2021-07-20	Abbvie Inc	métodos para o tratamento de hcv
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
AU2016283018C1 (en) *	2015-06-26	2022-03-03	Abbvie Inc.	Solid pharmaceutical compositions for treating HCV
CA2991417A1 (en) *	2015-07-08	2017-01-12	Abbvie Inc.	Methods for treating hcv
EA201890334A1 (ru) *	2015-07-17	2018-06-29	Эббви Инк.	Твердые фармацевтические композиции для лечения вируса гепатита с
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB202113944D0 (en) *	2021-09-29	2021-11-10	Univ Liverpool	Injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200800265A (en) *	2006-02-09	2008-01-01	Schering Corp	Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
AR075584A1 (es) *	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en) *	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
CN104023726A (zh) *	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
MX367796B (es) *	2012-09-18	2019-09-06	Abbvie Inc	Usos médicos para tratar hepatitis c.

2013
- 2013-09-17 MX MX2015003501A patent/MX367796B/es active IP Right Grant
- 2013-09-17 AU AU2013318302A patent/AU2013318302B2/en active Active
- 2013-09-17 DK DK13773463T patent/DK2897611T3/da active
- 2013-09-17 ES ES13773463T patent/ES2755089T3/es active Active
- 2013-09-17 PL PL13773463T patent/PL2897611T3/pl unknown
- 2013-09-17 LT LT13773463T patent/LT2897611T/lt unknown
- 2013-09-17 EP EP13773463.8A patent/EP2897611B1/en active Active
- 2013-09-17 SI SI201331607T patent/SI2897611T1/sl unknown
- 2013-09-17 RU RU2015114543A patent/RU2665365C2/ru active
- 2013-09-17 US US14/029,302 patent/US20140080868A1/en not_active Abandoned
- 2013-09-17 WO PCT/US2013/060103 patent/WO2014047039A1/en active Application Filing
- 2013-09-17 JP JP2015532139A patent/JP6297044B2/ja active Active
- 2013-09-17 RS RS20191378A patent/RS59640B1/sr unknown
- 2013-09-17 CN CN201380060100.7A patent/CN104797253A/zh active Pending
- 2013-09-17 PT PT137734638T patent/PT2897611T/pt unknown
- 2013-09-17 HU HUE13773463A patent/HUE046544T2/hu unknown
- 2013-09-17 NZ NZ630581A patent/NZ630581A/en unknown
- 2013-09-17 CA CA2884539A patent/CA2884539C/en active Active
- 2013-09-17 SG SG11201502095SA patent/SG11201502095SA/en unknown
- 2013-09-17 BR BR112015006037-4A patent/BR112015006037B1/pt active IP Right Grant
- 2013-09-17 EP EP19187747.1A patent/EP3597190A1/en active Pending
- 2013-09-17 SG SG10201702248UA patent/SG10201702248UA/en unknown
- 2013-09-18 TW TW102133969A patent/TWI621436B/zh active
2015
- 2015-03-13 ZA ZA2015/01752A patent/ZA201501752B/en unknown
- 2015-03-18 MX MX2019010600A patent/MX2019010600A/es unknown
- 2015-10-13 HK HK15109967.3A patent/HK1209319A1/xx unknown
2018
- 2018-02-19 JP JP2018026645A patent/JP6556884B2/ja active Active
- 2018-05-22 AU AU2018203608A patent/AU2018203608B2/en active Active
2019
- 2019-07-11 JP JP2019128933A patent/JP2019194241A/ja active Pending
- 2019-10-24 CY CY20191101109T patent/CY1122442T1/el unknown
- 2019-10-24 HR HRP20191939TT patent/HRP20191939T1/hr unknown
2020
- 2020-12-21 JP JP2020211042A patent/JP2021054849A/ja active Pending

Also Published As

Publication number	Publication date
JP2015528511A (ja)	2015-09-28
NZ630581A (en)	2017-02-24
BR112015006037B1 (pt)	2022-05-17
TWI621436B (zh)	2018-04-21
WO2014047039A1 (en)	2014-03-27
CY1122442T1 (el)	2021-01-27
JP6297044B2 (ja)	2018-03-20
ES2755089T3 (es)	2020-04-21
AU2013318302A1 (en)	2015-04-02
TW201412311A (zh)	2014-04-01
MX2019010600A (es)	2020-02-03
JP2019194241A (ja)	2019-11-07
RS59640B1 (sr)	2020-01-31
JP2018109035A (ja)	2018-07-12
EP2897611A1 (en)	2015-07-29
AU2013318302B2 (en)	2018-02-22
EP2897611B1 (en)	2019-07-24
ZA201501752B (en)	2016-08-31
SG11201502095SA (en)	2015-05-28
JP6556884B2 (ja)	2019-08-07
HK1209319A1 (en)	2016-04-01
RU2015114543A (ru)	2016-11-10
AU2018203608A1 (en)	2018-06-14
US20140080868A1 (en)	2014-03-20
HRP20191939T1 (hr)	2020-01-10
SI2897611T1 (sl)	2019-12-31
LT2897611T (lt)	2019-12-10
MX367796B (es)	2019-09-06
AU2018203608B2 (en)	2019-12-19
HUE046544T2 (hu)	2020-03-30
EP3597190A1 (en)	2020-01-22
CA2884539A1 (en)	2014-03-27
SG10201702248UA (en)	2017-04-27
CA2884539C (en)	2022-06-21
RU2665365C2 (ru)	2018-08-29
MX2015003501A (es)	2015-10-26
PL2897611T3 (pl)	2020-03-31
BR112015006037A2 (pt)	2017-07-04
JP2021054849A (ja)	2021-04-08
CN104797253A (zh)	2015-07-22
PT2897611T (pt)	2019-11-27

Publication	Publication Date	Title
IL269662A (en)	2019-11-28	Hepatitis C virus inhibitors
DK2906696T4 (da)	2023-02-27	Fremgangsmåder til modulering af c9orf72-ekspression
DK2709613T4 (da)	2020-11-16	Fremgangsmåder til behandling af hcv
DK2885010T3 (da)	2020-02-03	Fremgangsmåder til behandling med tauopati
DK2906698T3 (da)	2019-11-04	Fremgangsmåde til behandling af alports syndrom
DK2897620T3 (da)	2020-08-17	Fremgangsmåde til behandling af cancer
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
DK2897611T3 (da)	2019-11-04	Fremgangsmåder til behandling af hepatitis c
DK3454346T3 (da)	2021-11-01	Anordning til cylotronfremstilling af technetium-99m
DK3412687T3 (da)	2020-05-11	Fremgangsmåder til behandling af dlbcl
DK2854769T3 (da)	2023-06-26	Fremgangsmåder til behandling af artritis
DK3461895T3 (da)	2020-07-20	Modulation af ube3a-ats-ekspression
DK3626270T3 (da)	2024-01-15	Behandling af kardiovaskulære sygdomme
DK2857019T3 (da)	2020-08-17	Fremgangsmåde til behandling af multipel sklerose
DK3581199T3 (da)	2023-09-04	Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2961378T3 (da)	2019-11-25	Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK2836460T3 (da)	2022-10-10	Fremgangsmåde til fremstilling af graphen
DK2705847T3 (da)	2014-10-06	Sammensætning til behandling af psoriasis
DK2888228T3 (da)	2019-07-15	Inhibitorer af CD40-TRAF6 interaktion
DK2847363T3 (da)	2017-01-02	Fremgangsmåde til påføring af metal
DK2481821T3 (da)	2013-06-10	Fremgangsmåde til behandling af læder
DK2948143T3 (da)	2021-07-26	Anvendelse af phenoxypropylaminforbindelser til behandling af depression
DK2901162T3 (da)	2019-06-24	Fremgangsmåde til diagnosticering af muskeldystrofi
DK2694094T3 (da)	2017-11-13	FREMGANGSMÅDE TIL BEHANDLING AF IFN-alpha-RELATEREDE TILSTANDE
DK3473276T3 (da)	2024-01-29	Teknikker til behandling af abscesser